Bora Pharmaceuticals Reports Consolidated Revenue of NT$1.99 Billion in October

保瑞公告 10 月自結合併營收新台幣 19 億 9 仟萬元

Taipei, Taiwan, November 10, 2026 – Bora Pharmaceuticals Co., Ltd. (“Bora” or “the Company”) announced that its consolidated revenue for October 2026 reached NT$1.99 billion, up 15.91% year-over-year. Cumulative revenue for the year to date totaled NT$18,294 million, an increase of 10.11%.

台北，台灣，2026 年 11 月 10 日 – 保瑞藥業（以下簡稱「保瑞」，股票代碼：6472）今日公告 10 月自結合併營收為新台幣 19 億 9 仟萬元，年對年增加 15.91%；今年累計營收達新台幣 182.94 億，年增 10.11%。

Bora noted that its specialty and branded business, leading generics portfolio, and Weider Global Nutrition maintained solid momentum in October. Bora expects the seasonally strong fourth quarter to driver further growth.

保瑞指出，旗下數個市佔領先學名藥產品組合、專科與品牌藥產品線及威德品牌事業於 10 月持續展現穩健成長動能，預期第四季傳統旺季將進一步帶動營運表現。

However, October revenue was affected by two timing-related, non-recurring factors. First, Canada site shipments ran ~25% below orders on hand due to semi-solids line equipment issues; remediation is underway, with delayed volumes expected to ship within Q4. At the same time, high-potency orders for a customer in China were transitioned to a cost-optimized API supplier. Commercial batches will be released upon regulatory approval, with the associated revenue expected to be recognized in November.

然而，10 月營收主要受兩項時程因素影響。首先，加拿大廠半固體劑型產線因設備故障，當月出貨量約為在手訂單的 75%；目前修復作業進行中，預計遞延訂單可於第四季內完成交貨。第二，中國客戶的高活性產品訂單已於 10 月轉換至成本更具優勢的原料藥供應商，相關量產批次待監管機關核准後即可放行出貨，預計於 11 月認列遞延營收。

About Bora:

Founded in 2007, Bora Pharmaceuticals (“Bora” or “the Company”, 6472.TW and BORAY.OTCQX) is a leading pharmaceutical services company with a vision and goal of “Contributing to Better Health All Over the World”. Operating under a "Dual Engine" model that integrates CDMO and commercial expertise, we empower pharmaceutical and biotech partners to optimize product development, accelerate launches, and scale supply to meet global patient needs. At the same time, we actively broaden R&D and sales infrastructure, focusing on niche and rare disease markets to improve patients' quality of life.

By investing in talent, infrastructure, and biologics expansion, Bora continues to transform operations and achieve sustainable growth. Committed to making success "certain," Bora sets new standards in the pharmaceutical and CDMO industries.

For more, please visit:

https://www.bora-corp.com

https://www.boracdmo.com

關於保瑞：

保瑞藥業股份有限公司（股票代碼：6472.TW與BORAY.OTCQX）成立於2007年，是一家領先的製藥服務公司，自成立伊始即秉持「為全世界健康貢獻力量」的願景與目標。保瑞以整合 CDMO（委託開發與製造服務）與藥物開發銷售的「雙引擎」商業模式，協助製藥與生技合作夥伴優化產品開發流程、加速上市時程、擴大供應規模以滿足全球患者的需求。公司亦專注於美國的利基市場及罕見疾病領域，致力於透過拓展銷售通路實力提升患者的生活品質。

透過持續投資人才、生產與銷售及進入生物製劑業務領域，保瑞不斷推動業務升級與永續發展。我們以Making Success More Certain為為使命，專注高品質、高效率與可靠性，在製藥及 CDMO 領域樹立新標杆。

請造訪：

企業網站 https://www.bora-corp.com

CDMO 網站 https://www.boracdmo.com

Investor/Media enquiries　新聞聯繫人：

Nadiya Chen, Investor Relations　投資人關係　陳荻雅

+886 2 790-1555 Ext. 9108

Email：Nadiya.Chen@bora-corp.com